Cost perspective | Societal | 3rd party insurer |
---|---|---|
Ranibizumab therapy, direct ocular medical costsa | 79,056 | 79,056 |
Depressionb | (2543) | (2543) |
Injuryb | (664) | (664) |
Subacute Nursing Facility (SNF)b | (4100) | (4100) |
Nursing homeb | (19,046) | (19,046) |
Unexplained direct medical Medicare costsb | (28,598) | (28,598) |
Patient employment gaina | (9057) | – |
Paid caregivers released from jobsb | (82,419) | – |
Increased paid employment by freed-up unpaid caregiversa | (215,123) | – |
Total costs offsetting the direct ophthalmic medical costs | (361,573) | (54,974) |
Direct medical costs + offsetting costs = financial return to society | 282,517 | (24,082) |
Financial ROI for direct ophthalmic medical costs expended | 14.7% | −3.5% |
QALY gain: combined-eye model | 1.136 | 1.136 |
QALY gain: second-eye model | 1.372 | 1.372 |
VRQOL gain, combined-eye model | 16.3% | 16.3% |
VRQOL gain, second-eye model | 22.8% | 22.8% |
$/QALY, combined-eye model | (242,921) | 20,707 |
$/QALY, second-eye model | (205,916) | 17,552 |
Addition to GDP | 165,842 | 24,082 |
Financial ROI for GDP referent to direct ophthalmic medical costs expended | 7.0% | −11.4% |